Pfizer Inc (PFE)

Growth for business will continue, but not as fast as during Covid-19. Valuation coming back to better level. Trading at ~12x earnings which is better place to be. Would advise investors to compare business to peers. 

Had great success during the pandemic; their vaccine led. The company just offered growth warnings. He prefers Merck for its better valuation and their key drug Keytruda which makes up 35% of their revenue.

Not a fan. The kind of pharma company that buys companies for growth. The other kind builds their own pharmaceuticals from the ground up, and that's where he wants to be. Good business, but not one he wants exposure to. Further downside from here.

Great dividend, beat earnings last quarter. Cost cutting. Transitioning away from Covid. Very cheap at 9.5x 2024 earnings, 4% growth. At some point, it will stop falling, but not sure it's there yet. On price to growth, not nearly as attractive as MRK. Look elsewhere. 

Benefitted from Covid vaccines. Patent expirations in a couple of years. How will they continue to grow? Company is confident in acquisitions and internal R&D. She's looking at it, no decision yet. Cheap multiple, attractive yield. More of a deep value play.

MRK's done relatively better. Drugs going off patent also, but pipeline is a bit better. She's looking at this one too, still assessing.

Overall, a good company and it pays a 5% yield.

A good mix of consumer goods and healthcare, but the PE is extended. Prefers to buy Pfizer for its growth and lower PE. He might even roll the dice with Moderna. Or buy the IBB, biotech ETF.

Did extremely well through Covid, but that's now running off. Doing acquisitions to try to build future promise. His homework shows that MRK is a better opportunity. He also likes AMGN.

Cost-cutting, beat on Q2. In transition away from robustness of Covid. Looking to M&A to fill its pipeline. Very cheap at 10x versus the market at 20x. Only growing at 4.4%. Buying it down here won't hurt you. For heavy lifting, look to MRK or LLY. Yield is 4.6%.

Trades at 11x earnings. It benefited incredibly from Covid. There's nothing in the pipeline to drive the stock higher. Not expensive. Decent pipeline, which will benefit stock over next couple of years. Great dividend yield of 4%.

It would not be a top pick. It is more of a marketing engine as opposed to a company that develops drugs. It has made some poor acquisitions and there are better opportunities.

Disappointing since Covid. Great pipeline, good drugs that can become blockbusters. Valuation is 11x forward earnings, 6.5x trailing. Stock is basing around $35 support levels of 2020-21, and he's watching closely. Don't sell now. While you wait, you're getting a pretty decent yield of 4.5%.

Really cheap and pays a good dividend. But earnings keep falling. Are trying to get into the weight-loss space. Wait. Don't add to it.

They accumulated a lot of cash during Covid with their vaccine, but of course demand has fallen. They have a patent cliff in a few years, so they're buying companies to replace their drug pipeline and are developing drugs in-house. Shares have pulled back, so earnings will be negative in coming years. Trades at a decent PE. She may add, but will watch this.